ASCOM-WIRELESS-SOLUTIONS
Ascom Wireless Solutions, a global provider of mission-critical communication systems, has announced the launch of its ground-breaking mobile device, the Ascom Myco. It combines the capabilities of a smartphone with a set of features specifically designed for the healthcare environment, and especially for nurse communications and efficient management of clinical workflows.
Robust, reliable and made to last
The Ascom Myco has all the standard features of a smartphone, such as a touch screen, 3G and Wi-Fi, but in addition it has a robust design for withstanding knocks and drops, and also moisture and dust for maintaining hygiene. It has a long battery life as well as a rapid battery swap feature to keep the phone powered up without waiting for recharging. The size and weight are optimized so it can be operated with one hand and is comfortable to carry around on long nursing shifts.
Its range of communications capabilities make it a truly ground breaking product. Ascom’s long experience with voice over WiFi gives it a superior VoWiFi performance. A barcode reader enables patient and medicines identification for improved safety using current and coming technologies. Uniquely, the device has a top display that can show scrolling messages and a colored LED to show the priority of the message.
Integrated workflow intelligence in the palm of your hand
The integration software, Ascom Unite, connects with hospital information systems, patient monitors and nurse call systems. The user interface is designed to be easy to use and patient-centric. Nurses can be assigned to patients on their own device by simple ‘drag-and-drop’, giving them access to the patients’ records and lab reports and to receive automated messages, alerts and alarms for their allocated patients.
The interface makes it easy to filter and prioritize alerts, forward and escalate them, thus reducing the demand on the nurses. The nurse can see on the device what type of alert or alarm it is, the severity of the alarm, and which patient it is for, even when the device is in her breast pocket, as all necessary information is visible on the top display.
Truly purpose-built for clinical workflows and healthcare environments
Claes Ödman, General Manager, Ascom Wireless Solutions, says, “When developing Ascom Myco, our vision was to contribute to give nurses a chance to spend more time with their patients and thereby increase patient safety and satisfaction. To fulfill our vision we focused on three important areas: to reduce alarm fatigue, mobilize the information to the point of care and improve clinical workflows. I am proud to say that we have managed to come very far within all three areas. By collaborating with healthcare facilities, “shadowing” nurses during entire shifts and applying user-centric design methods, we have developed Ascom Myco with the whole healthcare team in mind. Ascom Myco has an attractive total cost of ownership since it is built to last in the demanding healthcare environments. It is flexible and designed to easily integrate into the IT architecture of a hospital or a care facility.
Superior communication capabilities for mission-critical information
Stefan Brämberg, Vice President Global Product Line Mobility, Ascom Wireless Solutions, concludes “Ascom Myco is a truly purpose-built smartphone for healthcare, targeted at caregivers and clinicians, which provides them with the information they need where it matters the most — at the heart of care. In addition, our middleware solution Ascom Unite, makes it a complete concept, creating a very powerful solution for mission-critical communication. We think that nurses are the heroes in healthcare and that they deserve their very own companion to assist them in their jobs, that’s why we named the smartphone Ascom Myco, where Myco stands for “My companion”.
ABOUT ASCOM WIRELESS SOLUTIONS
Ascom Wireless Solutions (www.ascom.com/ws) is a leading provider of on-site wireless communications for key segments such as hospitals , elderly care , independent living , manufacturing industries , secure establishments , retail and hotels . More than 75,000 systems are installed at major companies all over the world. The company offers a broad range of voice and professional messaging solutions, creating value for customers by supporting and optimizing their Mission-Critical processes. The solutions are based on VoWiFi , IP-DECT , nurse call and paging technologies, smartly integrated into existing enterprise systems. The company has subsidiaries in 13 countries and 1,200 employees worldwide. Founded in 1955 and based in Göteborg, Sweden, Ascom Wireless Solutions is part of the Ascom Group, listed on the Swiss Stock Exchange.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140930005068/en/
Contact:
For more information visit
www.ascommyco.com
or
Ascom
Wireless Solutions
Gunny Kron, +46 31 55 94 51
VP Global
Marketing & Communications
gunny.kron@ascom.se
or
Karin
Dunberg, +46 761 25 10 24
Marketing Communications
karin.dunberg@ascom.se
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum